Clinical Trials Browser

Recruiting × Biopsy × Gynecologic × Clear all

NCT05564377 2026-05-27

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05554328 2026-05-26

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT04633239 2026-05-22

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Phase 1 Recruiting

Recurrent Ovarian High Grade Serous Adenocarcinoma

NCT04550494 2026-05-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Phase 2 Recruiting

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT05950464 2026-05-11

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Phase 1 Recruiting

Endometrial Neoplasms

NCT05920798 2026-04-06

FRAPPE

Phase 1/2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04919629 2026-03-23

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06935344 2026-03-03

PROVE

Genetic Risk Score, Ovarian Neoplasms

NCT05465941 2026-02-09

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06815939 2026-01-29

OPTICS

Phase NA Recruiting

10,000 enrolled

GynecologicOther neoplasm

Urogenital Diseases, Genital Diseases, Uterine Cervical Diseases, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Precancerous Conditions, Urogenital Neoplasms, Uterine Diseases, Uterine Neoplasms

NCT07327489 2026-01-08

ELEPHAS-05

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasms, Skin Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04329494 2025-12-10

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Phase 1 Recruiting

GastrointestinalGynecologic

Appendiceal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT06639074 2025-10-02

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Phase 2 Recruiting

GynecologicSarcoma

Advanced Fallopian Tube Carcinoma

NCT05998135 2025-09-11

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Phase 2 Recruiting

Ovarian High Grade Serous Adenocarcinoma

NCT06289062 2024-11-05

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

Phase 2 Recruiting

Uterine Cervical Neoplasms